Discovery of N-methylpiperazinyl flavones as a novel class of compounds with therapeutic potential against Alzheimer’s disease: synthesis, binding affinity towards amyloid β oligomers (Aβo) and ability to disrupt Aβo-PrPC interactions
With no currently available disease-modifying drugs, Alzheimer’s disease is the most common type of dementia affecting over 47 million people worldwide. In light of the most recent discoveries placing the cellular prion protein (PrPC) as a key player in amyloid β oligomer (Aβo)-induced neurodegenera...
Main Authors: | Matos, A, Man, T, Idrissi, I, Souza, C, Mead, E, Dunbar, C, Wolak, J, Olivera, M, Evans, D, Grayson, J, Partridge, B, Garwood, C, Ning, K, Sharman, G, Chen, B, Rauter, A |
---|---|
Format: | Journal article |
Published: |
De Gruyter
2019
|
Similar Items
-
The role of PrPc in Alzheimer's disease related Amyloid-β hypothesis: a systematic review
by: Tomás Andrade Magalhães Gomes, et al.
Published: (2023-09-01) -
The Humanization and Maturation of an Anti-PrPc Antibody
by: Cheng Zhang, et al.
Published: (2024-02-01) -
Regulation of PrPC signaling and processing by dimerization
by: Xavier eRoucou
Published: (2014-10-01) -
PrPC from stem cells to cancer
by: Séverine eMartin-Lannerée, et al.
Published: (2014-09-01) -
The Functional Role of Prion Protein (PrPC) on Autophagy
by: Hae-Young Shin, et al.
Published: (2013-06-01)